Moving more potent and less toxic options to the frontline in the management of advanced lung cancer

Abstract

ALK and the development of the first approved ALK inhibitor crizotinibThe ALK gene is located on chromosome 2p in humans (24). The first ALK rearrangements identified in NSCLC were small inversions within chromosome 2p leading to the Editorial

Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer

“…Since that study, 1) 4 additional approvals in advNSCLC have been granted to 3 different anti‐PD‐(L)1 therapies; 2) the number of patients treated with PD‐(L)1 inhibitors and the follow‐up period have substantially increased; 3) scientific understanding of PD‐L1 testing has matured; 4) management has changed, including the practice of treating beyond RECIST‐defined progression based on the continued benefit observed in some cases after early “pseudoprogression” because of inflammatory response; and 5) recognition of the importance of progression and treatment‐based intermediate endpoints for patients has grown . Other drug approvals in the United States during this period, particularly for patients with EGFR mutations and ALK rearrangements, have also improved outcomes and treatment tolerability for patients with advNSCLC . These shifts underscore both the challenge and the urgency for assessing immunotherapy using real‐world endpoints.…”

“…[8][9][10][11][12] Other drug approvals in the United States during this period, particularly for patients with EGFR mutations and ALK rearrangements, have also improved outcomes and treatment tolerability for patients with advNSCLC. 13 These shifts underscore both the challenge and the urgency for assessing immunotherapy using real-world endpoints.…”